ASH 2025

Blood cells
#ASH 2025 #CAR-T #Events #Haematology #Oncology

ASH 2025: New clinical findings in haematology

The 67th American Society of Hematology (ASH) Annual Meeting and Exposition took place 6-9 December 2025, in Orlando, Florida. Diana Turner rounds up the latest clinical trial data shared at the meeting.  Early-stage trials KLN-1010 for multiple myeloma Kelonia Therapeutics announced the first results from the ongoing inMMyCAR study, a… Read More

#Exclusive Content

Scientist in laboratory
#ASH 2025 #Clinical trial #Graft vs Host Disease

MaaT013 shows strong survival rate in aGvHD patients 

New results reveal MaaT013 (Xervyteg) achieved a one-year overall survival rate of 54% for the treatment of patients with refractory severe acute Graft-versus-Host Disease (aGvHD).  The data was announced by biotechnology company MaaT Pharma at the American Society of Hematology (ASH) Annual Meeting and Exposition, currently taking place in Orlando, US. Read More

#News

Acute lymphoblastic leukemia
#ASH 2025 #Clinical trial #Leukaemia #Oncology

Pirtobrutinib more effective than ibrutinib, study finds 

A study into treatments for chronic lymphocytic leukaemia and small lymphocytic leukaemia (CLL/SLL) has found that Jaypirca (pirtobrutinib) is more effective than Imbruvica (ibrutinib).  The Phase III, first-of-its-kind BRUIN CLL-314 trial found that pirtobrutinib met its primary endpoint of non-inferiority on overall response rate (ORR) compared to ibrutinib. Pirtobrutinib, developed by Eli… Read More

#Cancer Research #News

Chronic myeloid leukaemia
#ASH 2025 #Leukaemia #Oncology

Drug shows ‘unprecedented’ response in chronic myeloid leukaemia 

Oncology company Terns Pharmaceuticals has announced encouraging results showing its candidate could be a best-in-class treatment for relapsed and refractory chronic myeloid leukaemia (CML).   The Phase I trial of TERN-701 showed a 64% major molecular response (MMR) achievement rate across all efficacy evaluable patients, also proving its safe and… Read More

#Cancer Research #News

CAR-T therapy for leukaemia
#ASH 2025 #Clinical trials #Drug discovery

CytoAgents announces positive preliminary data at ASH

Biotechnology company CytoAgents has presented preliminary safety data from its Phase Ib/IIa clinical trial of its lead drug candidate CTO1681. CTO1681 is an oral, small molecule immune modulator that uses a novel approach to prevent and mitigate both inflammation in the tumour microenvironment as well as toxicity frequently seen with… Read More

#News

Myeloma cells
#Arcellx #ASH 2025 #Myeloma

Anito-cel could be ‘significant’ treatment for myeloma 

Biotechnology company Arcellx has announced positive data from the Phase II study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM).  Results from the iMMagine-1 study demonstrate deep and durable responses with a predictable and manageable safety profile in a fourth-line or higher (4L+) RRMM population,… Read More

#Cancer Research #News

Haematology
#ASH 2025 #Sanofi #Systemic mastocytosis

Ayvakit is safe long-term treatment for systemic mastocytosis 

New results show Ayvakit (avapritinib) is an effective and safe long-term treatment for systemic mastocytosis (SM).  The data, announced by Sanofi company Blueprint Medicines, showed Ayvakit led to sustained symptom and quality-of-life benefits in indolent SM (ISM) after a median follow-up of more than three years, and extended survival rates in… Read More

#News

Red blood cells
#ASH 2025 #Blood can #JAK inhibitor #Myelofibrosis (MF) #Oncology

ASH 2025: Combined focus on myelofibrosis

More than a decade after first JAK approval, pharma looks to combination therapies to treat myelofibrosis. Pharma and biotech companies are looking to combination therapies for a new wave of treatments for the rare bone cancer myelofibrosis, building on the experience gathered over more than a decade with JAK inhibitors,… Read More

#Exclusive Content